Search
Citations & References (1)
Invitrogen™
LentiArray™ CRISPR Negative Control Lentivirus, human, non-targeting
Negative control gRNAs are essential in screening applications for setting thresholds for hit determination. The Invitrogen™ LentiArray™ CRISPR Negative ControlRead more
| Catalog Number | Quantity |
|---|---|
| A32327 | 1 mL |
Catalog number A32327
Price (TWD)
64,050.00
線上優惠
Ends: 31-Dec-2025
91,500.00Save 27,450.00 (30%)
Each
Quantity:
1 mL
Price (TWD)
64,050.00
線上優惠
Ends: 31-Dec-2025
91,500.00Save 27,450.00 (30%)
Each
Negative control gRNAs are essential in screening applications for setting thresholds for hit determination. The Invitrogen™ LentiArray™ CRISPR Negative Control Lentivirus, Human Scrambled, contains a gRNA sequence with no sequence homology to any region of the human genome.
For Research Use Only. Not for use in diagnostic procedures.
Specifications
For Use With (Application)Genome Editing
Product LineLentiArray
Product TypegRNA
Quantity1 mL
Shipping ConditionDry Ice
Control TypeNegative Control
FormatTube
RNAi TypegRNA
SpeciesHuman
Unit SizeEach
Contents & Storage
1 x 1 mL. Store at -68 to -85°C.
Citations & References (1)
Citations & References
Abstract
A functional screening of the kinome identifies the Polo-like kinase 4 as a potential therapeutic target for malignant rhabdoid tumors, and possibly, other embryonal tumors of the brain.
Journal:Pediatr Blood Cancer
PubMed ID:28398638
Malignant rhabdoid tumors (MRTs) are deadly embryonal tumors of the infancy. With poor survival and modest response to available therapies, more effective and less toxic treatments are needed. We hypothesized that a systematic screening of the kinome will reveal kinases that drive rhabdoid tumors and can be targeted by specific